Persistent but Dysfunctional Mucosal SARS-CoV-2-specific IgA and Low Lung IL-1β Associate with COVID-19 Fatal Outcome: A Cross-sectional Analysis

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Oct 17

PMID 36248831

Authors

Maria Julia Ruiz

Gabriel Siracusano

Andrea Cottignies-Calamarte

Daniela Tudor

Fernando Real

Aiwei Zhu

Claudia Pastori

Claude Capron

Arielle R Rosenberg

Nigel Temperton

Diego Cantoni

Hanqing Liao

Nicola Ternette

Pierre Moine

Mathieu Godement

Guillaume Geri

Jean-Daniel Chiche

Djillali Annane

Elisabeth Cramer Borde

Lucia Lopalco

Morgane Bomsel

Affiliations

Soon will be listed here.

Abstract

Highlights: Mucosal pulmonary antibody response in COVID-19 outcome remains unclear. We show that in severe COVID-19 patients, mucosal pulmonary non-neutralizing SARS-CoV-2 IgA persit after viral clearance in the lung. Furthermore, low lung IL-1β correlate with fatal COVID-19. Altogether, mucosal IgA may exert harmful functions beside protective neutralization.

Citing Articles

A Possible Protective Effect of IgA Against Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) in Bronchoalveolar Lavage in COVID-19 Patients Admitted to Intensive Care Unit.

Di Stefano M, Mirabella L, Cotoia A, Faleo G, Rauseo M, Rizzo A Viruses. 2025; 16(12.

PMID: 39772161 PMC: 11680283. DOI: 10.3390/v16121851.

Impaired mucosal IgA response in patients with severe COVID-19.

Yaugel-Novoa M, Noailly B, Jospin F, Pizzorno A, Traversier A, Pozzetto B Emerg Microbes Infect. 2024; 13(1):2401940.

PMID: 39358866 PMC: 11451292. DOI: 10.1080/22221751.2024.2401940.

The Seraph 100 Microbind Affinity Blood Filter Does Not Alter Levels of Circulating or Mucosal Antibodies in Critical COVID-19 Patients.

Conner T, Vir P, Laing E, Stewart I, Mitre E, Pratt K Antibodies (Basel). 2024; 13(3).

PMID: 39189236 PMC: 11348046. DOI: 10.3390/antib13030065.

CGRP inhibits SARS-CoV-2 infection of bronchial epithelial cells, and its pulmonary levels correlate with viral clearance in critical COVID-19 patients.

Barbosa Bomfim C, Genin H, Cottoignies-Callamarte A, Gallois-Montbrun S, Murigneux E, Sams A J Virol. 2024; 98(9):e0012824.

PMID: 39162434 PMC: 11406896. DOI: 10.1128/jvi.00128-24.

The longitudinal characterization of immune responses in COVID-19 patients reveals novel prognostic signatures for disease severity, patients' survival and long COVID.

Noviello M, De Lorenzo R, Chimienti R, Maugeri N, De Lalla C, Siracusano G Front Immunol. 2024; 15:1381091.

PMID: 39136010 PMC: 11317765. DOI: 10.3389/fimmu.2024.1381091.

References

Hoepel W, Chen H, Geyer C, Allahverdiyeva S, Manz X, de Taeye S . High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages. Sci Transl Med. 2021; 13(596). PMC: 8158960. DOI: 10.1126/scitranslmed.abf8654. View

Di Genova C, Sampson A, Scott S, Cantoni D, Mayora-Neto M, Bentley E . Production, Titration, Neutralisation, Storage and Lyophilisation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Lentiviral Pseudotypes. Bio Protoc. 2021; 11(21):e4236. PMC: 8595416. DOI: 10.21769/BioProtoc.4236. View

Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel K . Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020; 5(12):1598-1607. PMC: 7610833. DOI: 10.1038/s41564-020-00813-8. View

Alu A, Chen L, Lei H, Wei Y, Tian X, Wei X . Intranasal COVID-19 vaccines: From bench to bed. EBioMedicine. 2022; 76:103841. PMC: 8785603. DOI: 10.1016/j.ebiom.2022.103841. View

Rogers T, Zhao F, Huang D, Beutler N, Burns A, He W . Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020; 369(6506):956-963. PMC: 7299280. DOI: 10.1126/science.abc7520. View

Roltgen K, Boyd S . Antibody and B cell responses to SARS-CoV-2 infection and vaccination. Cell Host Microbe. 2021; 29(7):1063-1075. PMC: 8233571. DOI: 10.1016/j.chom.2021.06.009. View

Chen P, Bobrovitz N, Premji Z, Koopmans M, Fisman D, Gu F . SARS-CoV-2 shedding dynamics across the respiratory tract, sex, and disease severity for adult and pediatric COVID-19. Elife. 2021; 10. PMC: 8504968. DOI: 10.7554/eLife.70458. View

Banerjee A, El-Sayes N, Budylowski P, Jacob R, Richard D, Maan H . Experimental and natural evidence of SARS-CoV-2-infection-induced activation of type I interferon responses. iScience. 2021; 24(5):102477. PMC: 8074517. DOI: 10.1016/j.isci.2021.102477. View

Caniego-Casas T, Martinez-Garcia L, Alonso-Riano M, Pizarro D, Carretero-Barrio I, Martinez-de-Castro N . RNA SARS-CoV-2 Persistence in the Lung of Severe COVID-19 Patients: A Case Series of Autopsies. Front Microbiol. 2022; 13:824967. PMC: 8841799. DOI: 10.3389/fmicb.2022.824967. View

10.

Brandtzaeg P . Secretory IgA: Designed for Anti-Microbial Defense. Front Immunol. 2013; 4:222. PMC: 3734371. DOI: 10.3389/fimmu.2013.00222. View

11.

Sagar M, Reifler K, Rossi M, Miller N, Sinha P, White L . Recent endemic coronavirus infection is associated with less-severe COVID-19. J Clin Invest. 2020; 131(1). PMC: 7773342. DOI: 10.1172/JCI143380. View

12.

Delclaux C, Roupie E, Blot F, Brochard L, Lemaire F, Brun-Buisson C . Lower respiratory tract colonization and infection during severe acute respiratory distress syndrome: incidence and diagnosis. Am J Respir Crit Care Med. 1997; 156(4 Pt 1):1092-8. DOI: 10.1164/ajrccm.156.4.9701065. View

13.

Pelaia C, Tinello C, Vatrella A, De Sarro G, Pelaia G . Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications. Ther Adv Respir Dis. 2020; 14:1753466620933508. PMC: 7298425. DOI: 10.1177/1753466620933508. View

14.

Yoshida T, Mei H, Dorner T, Hiepe F, Radbruch A, Fillatreau S . Memory B and memory plasma cells. Immunol Rev. 2010; 237(1):117-39. DOI: 10.1111/j.1600-065X.2010.00938.x. View

15.

Guo Y, Cao Q, Hong Z, Tan Y, Chen S, Jin H . The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020; 7(1):11. PMC: 7068984. DOI: 10.1186/s40779-020-00240-0. View

16.

Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin J, Olsson A . Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020; 183(1):158-168.e14. PMC: 7427556. DOI: 10.1016/j.cell.2020.08.017. View

17.

Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J . Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021; 592(7854):438-443. DOI: 10.1038/s41586-021-03402-9. View

18.

Khamassi M, Xu L, Rey J, Duchemin M, Bouceba T, Tuffery P . The CH1α domain of mucosal gp41 IgA contributes to antibody specificity and antiviral functions in HIV-1 highly exposed Sero-Negative individuals. PLoS Pathog. 2020; 16(12):e1009103. PMC: 7802955. DOI: 10.1371/journal.ppat.1009103. View

19.

Meyer-Bahlburg A . B-1 cells as a source of IgA. Ann N Y Acad Sci. 2015; 1362:122-31. DOI: 10.1111/nyas.12801. View

20.

Padoan A, Sciacovelli L, Basso D, Negrini D, Zuin S, Cosma C . IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study. Clin Chim Acta. 2020; 507:164-166. PMC: 7194886. DOI: 10.1016/j.cca.2020.04.026. View